PXMD (PaxMedica) Other Financing: $-0.52 Mil (TTM As of Sep. 2024)


What is PaxMedica Other Financing?

PaxMedica PXMD Other Financing is $-0.52 Mil as of Sep. 2024.

PaxMedica's Other Financing for the three months ended in Sep. 2024 was $0.00 Mil.

PaxMedica's Other Financing for the trailing twelve months (TTM) ended in Sep. 2024 was $-0.52 Mil.

PaxMedica Other Financing Historical Data

* Premium members only.

The historical data trend for PaxMedica's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PaxMedica Other Financing Chart

PaxMedica Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Financing
Get a 7-Day Free Trial 0.00 0.52 -0.17 -0.04 -0.82

PaxMedica Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.06 -0.52 0.00 0.00 0.00

PaxMedica Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.52 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of $-0.52 Mil mean?
PaxMedica (PXMD) has a Other Financing of $-0.52 Mil as of Sep. 2024. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for PaxMedica and its competitors.
Is PaxMedica's Other Financing too high?
PaxMedica's current Other Financing is $-0.52 Mil.
How does PaxMedica's Other Financing compare to BTAX and NBIO?
PaxMedica's Other Financing of $-0.52 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Biotechnology company?
A good Other Financing depends on the Biotechnology industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for PaxMedica and its competitors. PaxMedica's current Other Financing is $-0.52 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PaxMedica stock overvalued right now?
PaxMedica (PXMD) has a current Other Financing of $-0.52 Mil. The current Other Financing is $-0.52 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For PaxMedica (PXMD), the current Other Financing is $-0.52 Mil as of Sep. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PaxMedica Business Description

Address 303 South Broadway, Suite 125, Tarrytown, NJ, USA, 10591
PaxMedica Inc is a clinical-stage biopharmaceutical company focusing on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms, ranging from neurodevelopmental disorders, including autism spectrum disorder (ASD), to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), a debilitating physical and cognitive disorder believed to be viral in origin and now with rising incidence globally due to the long term effects of SARS-CoV-2 (COVID-19). The company's product candidate under development is PAX-101, an intravenous formulation of suramin, which it is developing for multiple indications, including East African HAT, ASD, ME/CFS, and LCS.